Biosurgery: A New Frontier in Life Sciences

Strategic Insights -

Biosurgery, a nascent discipline seeking to revolutionize wound healing and bone repair through the development of engineered tissues and organs, is slowly gaining momentum. Despite the enormous potential of this field, its commercial value is estimated to be 10 to 15 years away. Many companies have already failed or been acquired in the process of trying to capitalize on this emerging technology. However, a few early leaders, including major corporations and small startups, have managed to secure funding and partnerships to push their biosurgery advances forward.

Key Takeaways:

  • Baxter BioSurgery, a division of Baxter International Inc., has been at the forefront of biosurgery deals, acquiring several companies in the past seven years, including Fusion Medical Technologies Inc. for $157 million in 2002.
  • The most successful deal for Baxter was the acquisition of Fusion, which has generated $15 million in revenue for Fusion in 2001 and led to the development of the FloSeal Hemostatic Matrix product.
  • Major corporations like Genzyme Corp. and IsoTis OrthoBiologics Inc. are also positioning themselves to capitalize on the potential of biosurgery, with Genzyme's subsidiary, Genzyme Biosurgery, being one of the biggest players in the field.
  • Small startups like MacroPore Biosurgery Inc. and Confluent Surgical Inc. are also making headway in the field, with MacroPore receiving a $5 million milestone payment from Medtronic Inc. for completing the evaluation of a bio-resorbable implant system.
  • The orthobiologics market is expected to expand to $1.5 billion next year, with IsoTis OrthoBiologics Inc. hoping to grab a small slice of this market with its orthobiologic products for musculoskeletal repair.
  • Larger medical device companies like Medtronic Inc. and Boston Scientific Corp. may also enter the sector in earnest, potentially paving the way for additional acquisitions and dealmaking.

Statistics:

  • Baxter BioSurgery acquired Fusion Medical Technologies Inc. for $157 million in 2002.
  • The FloSeal Hemostatic Matrix product generated $15 million in revenue for Fusion in 2001.
  • Genzyme Biosurgery was formed through the merger of Genzyme Surgical Products, Genzyme Tissue Repair, and Biomatrix Inc. in 2000, with the combined company valued at approximately $1 billion.
  • The orthobiologics market is expected to expand to $1.5 billion next year.
  • IsoTis OrthoBiologics Inc. recorded a loss of $24.4 million in 2002.

Sources:

  • "Biosurgery: A New Frontier in Life Sciences" by Joshua Jaffe, TheDeal.com
  • Baxter International Inc. website
  • Genzyme Corp. website
  • IsoTis OrthoBiologics Inc. website
  • MacroPore Biosurgery Inc. website
  • Confluent Surgical Inc. website